» Articles » PMID: 20192902

Oxime K027: Novel Low-toxic Candidate for the Universal Reactivator of Nerve Agent- and Pesticide-inhibited Acetylcholinesterase

Overview
Specialty Biochemistry
Date 2010 Mar 3
PMID 20192902
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Oxime K027 is a low-toxic bisquaternary compound originally developed as a reactivator of acetylcholinesterase (AChE) inhibited by nerve agents. The reactivation potency of K027 has been tested as a potential reactivator of AChE inhibited by tabun, sarin, cyclosarin, soman, VX, Russian VX, paraoxon, methylchlorpyrifos, and DDVP. The results show that oxime K027 reactivated AChE inhibited by almost all tested inhibitors to more than 10%, which is believed to be enough for saving the lives of intoxicated organisms. In the case of cyclosarin- and soman-inhibited AChE, oxime K027 did not reach sufficient reactivation potency.

Citing Articles

Experimental and Established Oximes as Pretreatment before Acute Exposure to Azinphos-Methyl.

Lorke D, Nurulain S, Hasan M, Kuca K, Petroianu G Int J Mol Sci. 2021; 22(6).

PMID: 33802843 PMC: 8002820. DOI: 10.3390/ijms22063072.


Combined Pre- and Posttreatment of Paraoxon Exposure.

Lorke D, Nurulain S, Hasan M, Kuca K, Petroianu G Molecules. 2020; 25(7).

PMID: 32230733 PMC: 7180863. DOI: 10.3390/molecules25071521.


The Experimental Oxime K027-A Promising Protector From Organophosphate Pesticide Poisoning. A Review Comparing K027, K048, Pralidoxime, and Obidoxime.

Lorke D, Petroianu G Front Neurosci. 2019; 13:427.

PMID: 31191210 PMC: 6547910. DOI: 10.3389/fnins.2019.00427.


A 7-methoxytacrine-4-pyridinealdoxime hybrid as a novel prophylactic agent with reactivation properties in organophosphate intoxication.

Nepovimova E, Korabecny J, Dolezal R, Nguyen T, Jun D, Soukup O Toxicol Res (Camb). 2018; 5(4):1012-1016.

PMID: 30090408 PMC: 6062411. DOI: 10.1039/c6tx00130k.


Acetylcholinesterase Inhibitors and Drugs Acting on Muscarinic Receptors- Potential Crosstalk of Cholinergic Mechanisms During Pharmacological Treatment.

Soukup O, Winder M, Killi U, Wsol V, Jun D, Kuca K Curr Neuropharmacol. 2016; 15(4):637-653.

PMID: 27281175 PMC: 5543679. DOI: 10.2174/1570159X14666160607212615.